Cullinan Therapeutics: A Biotech with Multiple Value Drivers and a Strong Cash Position

Cullinan Therapeutics is a clinical-stage drug developer with a focus on autoimmune and blood cancer treatments, as well as a late-stage partnered lung cancer asset, zipalertinib. The company has a wholly owned pipeline of bispecific T-cell engagers and has initiated a rolling BLA submission with Taiho for zipalertinib. Cullinan is also cash-rich with a strong balance sheet, providing multiple value drivers for investors.